New drug cocktail aims to tame Hard-to-Treat myeloma
NCT ID NCT04764942
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 30 times
Summary
This study tests a new combination of drugs for people with multiple myeloma that has returned and no longer responds to standard treatments. The main drug, selinexor, blocks a protein that helps cancer cells survive. It is given with pomalidomide, dexamethasone, and sometimes carfilzomib. The goal is to find the best dose and see how well the combination controls the cancer. About 39 adults with relapsed or refractory multiple myeloma will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.